CONTEXT: Fatigue is the most common sequela among non-small cell lung cancer (NSCLC) survivors one to six years post-treatment and is associated with functional limitations. OBJECTIVES: This study examined the prevalence, severity, and correlates of fatigue among early stage NSCLC survivors. METHODS: Three-hundred fifty individuals diagnosed and surgically treated for Stage IA or IB NSCLC completed a survey that included the Brief Fatigue Inventory (BFI) to assess the prevalence and severity of fatigue. The Karnofsky Self-Reported Performance Rating scale (SR-KPS) was used as a measure of functional status and was compared with the severity of fatigue through Chi-squared analyses. Demographic, psychological, and medical correlates of fatigue were examined using logistic regression. RESULTS: The prevalence of fatigue was 57%. Forty-one percent (n=142) of participants had mild fatigue and 16.8% (n=59) had moderate or severe fatigue (BFI≥4). Among the individuals reporting moderate or severe fatigue, 23.7% (n=14) had significant functional impairment (SR-KPS≤70%) compared with 2.8% (n=8) with mild or no fatigue (χ(2)=58.1, P<0.001). In the multivariate analysis, NSCLC survivors with pulmonary disease (odds ratio [OR]=2.28), depressive symptoms (OR=6.99), and anxiety symptoms (OR=2.31) were more likely to report experiencing clinically significant fatigue, whereas those who met physical activity guidelines (OR=0.29) reported less fatigue. CONCLUSION: Fatigue is highly prevalent among NSCLC survivors and associated with more functional impairment. A comprehensive approach to the treatment of fatigue includes the screening and management of anxious and depressive symptoms, and pulmonary disorders such as chronic obstructive pulmonary disease.
CONTEXT: Fatigue is the most common sequela among non-small cell lung cancer (NSCLC) survivors one to six years post-treatment and is associated with functional limitations. OBJECTIVES: This study examined the prevalence, severity, and correlates of fatigue among early stage NSCLC survivors. METHODS: Three-hundred fifty individuals diagnosed and surgically treated for Stage IA or IB NSCLC completed a survey that included the Brief Fatigue Inventory (BFI) to assess the prevalence and severity of fatigue. The Karnofsky Self-Reported Performance Rating scale (SR-KPS) was used as a measure of functional status and was compared with the severity of fatigue through Chi-squared analyses. Demographic, psychological, and medical correlates of fatigue were examined using logistic regression. RESULTS: The prevalence of fatigue was 57%. Forty-one percent (n=142) of participants had mild fatigue and 16.8% (n=59) had moderate or severe fatigue (BFI≥4). Among the individuals reporting moderate or severe fatigue, 23.7% (n=14) had significant functional impairment (SR-KPS≤70%) compared with 2.8% (n=8) with mild or no fatigue (χ(2)=58.1, P<0.001). In the multivariate analysis, NSCLC survivors with pulmonary disease (odds ratio [OR]=2.28), depressive symptoms (OR=6.99), and anxiety symptoms (OR=2.31) were more likely to report experiencing clinically significant fatigue, whereas those who met physical activity guidelines (OR=0.29) reported less fatigue. CONCLUSION:Fatigue is highly prevalent among NSCLC survivors and associated with more functional impairment. A comprehensive approach to the treatment of fatigue includes the screening and management of anxious and depressive symptoms, and pulmonary disorders such as chronic obstructive pulmonary disease.
Authors: Young Ho Yun; Xin Shelley Wang; Jung Suk Lee; Ju Won Roh; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Tito R Mendoza; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2005-02 Impact factor: 3.612
Authors: C M Mangione; L Goldman; E J Orav; E R Marcantonio; A Pedan; L E Ludwig; M C Donaldson; D J Sugarbaker; R Poss; T H Lee Journal: J Gen Intern Med Date: 1997-11 Impact factor: 5.128
Authors: Andrea L Dunn; Madhukar H Trivedi; James B Kampert; Camillia G Clark; Heather O Chambliss Journal: Am J Prev Med Date: 2005-01 Impact factor: 5.043
Authors: Patricia M Kenny; Madeleine T King; Rosalie C Viney; Michael J Boyer; Christine A Pollicino; Jocelyn M McLean; Michael J Fulham; Brian C McCaughan Journal: J Clin Oncol Date: 2007-12-17 Impact factor: 44.544
Authors: Yoon Jung Chang; Jung Suk Lee; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Xin Shelley Wang; Tito R Mendoza; Charles S Cleeland; Young Ho Yun Journal: Support Care Cancer Date: 2007-07 Impact factor: 3.359
Authors: D Howell; S Keller-Olaman; T K Oliver; T F Hack; L Broadfield; K Biggs; J Chung; D Gravelle; E Green; M Hamel; T Harth; P Johnston; D McLeod; N Swinton; A Syme; K Olson Journal: Curr Oncol Date: 2013-06 Impact factor: 3.677
Authors: Paul Krebs; Elliot J Coups; Marc B Feinstein; Jack E Burkhalter; Richard M Steingart; Amy Logue; Bernard J Park; Jamie S Ostroff Journal: J Cancer Surviv Date: 2011-07-02 Impact factor: 4.442
Authors: Amy E Lowery; Paul Krebs; Elliot J Coups; Marc B Feinstein; Jack E Burkhalter; Bernard J Park; Jamie S Ostroff Journal: Support Care Cancer Date: 2013-09-10 Impact factor: 3.603
Authors: Timothy J Williamson; Alyssa K Choi; Julie C Kim; Edward B Garon; Jenessa R Shapiro; Michael R Irwin; Jonathan W Goldman; Krikor Bornyazan; James M Carroll; Annette L Stanton Journal: J Thorac Oncol Date: 2018-07-05 Impact factor: 15.609
Authors: Errol J Philip; Elliot J Coups; Marc B Feinstein; Bernard J Park; Donna J Wilson; Jamie S Ostroff Journal: Support Care Cancer Date: 2013-10-05 Impact factor: 3.603